Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-11
2005-10-11
Carlson, Karen Cochrane (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C436S065000, C514S253130, C435S069200
Reexamination Certificate
active
06953774
ABSTRACT:
The present invention relates to methods of inducing ovulation in a female host comprising the administration of a non-polypeptide cyclic adenosine monophosphate (cAMP) level modulator to the female host. In another aspect, the invention provides for specific administration of the phosphodiesterase inhibitor prior to the luteal phase of the host's ovulatory cycle. Preferred non-polypeptide cAMP level modulator include phosphodiesterase inhibitors, particularly inhibitors of phosphodiesterase type 4.
REFERENCES:
patent: 4338305 (1982-07-01), Corbin
patent: 5087615 (1992-02-01), Chappel
patent: 5643877 (1997-07-01), Zohar et al.
patent: 5710160 (1998-01-01), Guay et al.
patent: 5710170 (1998-01-01), Guay et al.
patent: 5958926 (1999-09-01), Garvey et al.
patent: 6100270 (2000-08-01), Campbell
patent: 6110471 (2000-08-01), Conti et al.
patent: 6303789 (2001-10-01), Bar
patent: 6316457 (2001-11-01), Garvey et al.
patent: 6316472 (2001-11-01), Frenette et al.
patent: 6423710 (2002-07-01), Martins et al.
patent: WO 97/42174 (1997-11-01), None
patent: WO 97/44036 (1997-11-01), None
patent: WO 97/44322 (1997-11-01), None
patent: WO 97/44337 (1997-11-01), None
patent: WO 97/48697 (1997-12-01), None
patent: WO 97/49702 (1997-12-01), None
patent: WO 98/02440 (1998-01-01), None
patent: WO 98/14432 (1998-04-01), None
patent: WO 98/18796 (1998-05-01), None
patent: WO 98/20007 (1998-05-01), None
Catherine, S.-L. et al. (1999) Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. Proc. Natl. Acad. Sci. U S A. vol. 96, pp. 11998-2003.
Reference A; Current patents Gazette (Apr. 30 1999) “Drug patening in context”.
Stevents, J. C. et al. (1997) Human liver CYP2B6-catalyzed hydroxylation of RP 73401. J. Pharmacol. Exp. Ther. vol. 282, pp. 1389-1395.
Zhang, W. et al. (2002) Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. Mol. Pharmacol. vol. 62, pp. 514-520.
Travadi, J. N. et al. (2003) Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr. Pulmonol. vol. 36, pp. 529-535. Review.
Conti, M. (2000) Phosphodiesterases and cyclic nucleotide signaling in endocrine cells. Mol. Endocrinol. vol. 14, pp. 1317-2137. Review.
Bowman, W. C. et al. (1980) in “Texbook of Pharmacology”, the 2ndedition, pp. 20.20-20.21, Blackwell Scientific Publication.
Brito, et al, “Type 4 Phosphodiesterase Inhibitors and their Potential in the Treatment of Inflammatory Disease”, Chapter 12,Emerging Drugs: The Prospect for Improved Medicines, Ashley Publications Ltd., ISSN 1361-9195: 2:249-268 (1997).
Conti, M., “Phosphodiesterases and Cyclic Nucleotide Signaling in Endocrine Cells”,Molecular Endocrinology, 14(9):1317-1327 (2000).
Cooke, G.M. “Differential Effects of Tritostane and Cyanoketone on the 3 Beta-Hydroxysteroid Dehydrogenase-Isomerase Reactions in Androgen and 16-Androstene Biosynthetic Pathways in the Pig Testis”,J Steroid Biochem Mol Biol58:1 95-101 (1996).
M. Filicori, “Ovulation Induction: Gonadotropin-Releasing Hormone and Its Agonists”,Reproductive Endocrinology, Surgery, and Technology, vol. 2, Chapter 61, Lippincott-Raven Publishers, Philadelphia (1996).
S. Franks et al., “Ovulation Induction: Gonadotropins”,Reproductive Endocrinology, Surgery, and Technology, vol. 2, Chapter 60, Lippincott-Raven Publishers, Philadelphia (1996).
Hassan, et al, “Phosphodiesterase Inhibitor Improved Responsiveness to Gonadotropins in Low Responders”,Fertility&Sterility, S249: 489, Alexandria ICSHVF Center, Alexandria, Egypt.
Karlsson, et al. “Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis”,Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 7(9):989-1003 (1997).
Movsesian, M., “Therapeutic Potential of Cyclic Nucleotide Phosphodiesterase Inhibitors in Heart Failure”Exp. Opin. Invest. Drugs, Ashley Publications Ltd., ISSN 1354-3784, 9(5):963-973 (2000).
Norman, P., “PDE4 Inhibitors 1999”,Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 9(8): 1101-1118 (1999).
O'Donnell, J., “William Harvey Research Conference on PDE Inhibitors: Drugs with an Expanding Range of Therapeutic Uses”,Exp. Opin. Invest. Drugs, Ashley Publications Ltd., ISSN 1354-3784, 9(3):621-625 (2000).
“Patent Evaluation: Nicotinamide Derivatives as Selective Inhibitors of PDE4: Pfizer Products, Inc. WO9845268”,Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 9(4):481-485 (1999).
“Patent Evaluation: Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: Phosphodiesterase 4 Inhibitors: Ceiitech Therapeutics Ltd.: WO9723460 & WO9723461”,Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 7(11):1355-1357 (1977).
“Patent Evaluation: Substituted Indazole Derivatives and their use as Inhibitors of PDE4 and the Production of Turnour Necrosis Factor: Pfizer, Inc.: WO9742174”,Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 8(8):1053-1058 (1998).
“Patent Evaluation: A Heterogeneous Collection of Novel Phosphodiesterase Type 4 Inhibitors”,Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 8(11):1529-1536 (1998).
“Patent Evaluation: Benzofuran and Quinoline Carboxamides and Quinoline Sulfonamides as TNF Inhibitors and as PDE4 inhibitors: Chiroscience Ltd.: WO9744337, WO9744036, WO9744322”,Exp. Opin. Ther. Patents, Ashley Publications Ltd., ISSN 1354-3776, 8(7):899-905 (1998).
R. Philosophie et al., “Gonadotropin-Induced Ovulation”,Reproductive Endocrinology, Surgery, and Technology, vol. 1, Chapter 54, Lippincott-Raven Publishers, Philadelphia (1996).
Shetty, et al. “Effect of Estrogen Deprivation on the Reproductive Physiology of Male and Female Primates”,J. Steroid Biochem Mol Biol61:3-6, 157-166 (1997).
Van Loon, “In utero exposure to gonadotrophins”,Female Infertility Therapy Current Practice, Chapter 1, Shoham, et al. (Eds.), Martin Dunitz Ltd., London (1999).
Shughrue et al., “Regulation of Progesterone Receptor Messenger Ribonucleic Acid in the Rat Medial Preoptic Nucleus by Estrogenic and Antiestrogenic Compounds: an in situ hybridization study”,Endocrinology, 138:12, 5476-5484 (1999).
A. Tsafriri et al., “Ovulation”,Reproductive Endocrinology, Surgery, and Technology, vol. 1, Chapter 11, Lippincott-Raven Publishers, Philadelphia (1996).
Turner, et al., “Effect of Chronic Administration of an Aromatase Inhibitor to Adult Male Rats on Pituitary and Testicular Function and Fertility”,J. Endocrinol, 164:2, 225-238 (2000).
Chappel et al., “Basic Knowledge About Recombinant Gonadotrophic Hormone Production”,Female Infertility Therapy Current Practice, Chapter 9, Shoham, et al. (Eds.), Martin Dunitz Ltd., London (1999).
Tsafriri, A., et al., “Oocyte Maturation Involves Compartmentalization and Opposing Change of cAMP Levels in Follicular Somatic and Germ Cells: Studies Using Selective Phosphodiesterase Inhibitors,” Developmental Biology, vol. 178, pp. 393-402 (1996).
Eshkol Aliza
MacNamee Michael C.
McKenna Sean
Palmer Stephen
Tepper Mark
Applied Research Systems Ars Holding N.V.
Carlson Karen Cochrane
Clough David W.
Howrey LLP
Liu Samuel W.
LandOfFree
Methods of inducing ovulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inducing ovulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inducing ovulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3467261